Real-time detection of influenza virus
The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.
1. A system for detecting an influenza viral particle in a sample of bodily fluid, the system comprising:
a sample collection unit configured to receive the sample of bodily fluid from a subject suspected to contain the influenza viral particle;
an assay assembly in fluidic communication with the sample collection unit, the assay assembly comprising a first reagent chamber, a second reagent chamber, a reaction site, and a fluidic channel that connects the first and second reagent chambers with the reaction site, wherein the first reagent chamber comprises a first immunoassay reagent and the second reagent chamber comprises a second immunoassay reagent;
a waste chamber in fluidic communication with the assay assembly; and
a reader assembly comprising a detection assembly,
wherein the assay assembly is configured to:
receive the sample from the sample collection unit;
release the first and second immunoassay reagents from the first and second reagent chambers to the reaction site through the fluidic channel by one or more actuating elements;
allow the sample to react with the first and second immunoassay reagents at the reaction site, wherein the first immunoassay reagent binds to a hemagglutinin molecule to form a first immune complex on the influenza viral particle, and wherein the second immunoassay reagent binds to a neuraminidase molecule to form a second immune complex on the influenza viral particle; and
yield one or more signals indicative of the simultaneous presence of hemagglutinin and neuraminidase on the influenza viral particle based on the first and second immune complexes; and
wherein the detection assembly is configured to:
detect the influenza viral particle in the sample based on detection of the one or more signals indicative of the simultaneous presence of hemagglutinin and neuraminidase.
2. The system of claim 1 , wherein the one or more actuating elements comprise at least one pump and one valve to control and direct movement of fluids in the system.
3. The system of claim 1 , wherein detection of the one or more signals indicative of the simultaneous presence of hemagglutinin and neuraminidase is indicative of an influenza type A viral infection.
4. The system of claim 1 , wherein detection of the one or more signals indicative of the simultaneous presence of hemagglutinin and neuraminidase is indicative of an influenza type B viral infection.
5. The system of claim 1 , wherein the hemagglutinin is selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16, and the neuraminidase is selected from the group consisting of N1, N2, N3, N4, and N5.
6. The system of claim 1 , wherein the hemagglutinin is H5 and the neuraminidase is N1.
7. The system of claim 1 , wherein the assay assembly comprises an immunoassay assembly.
8. The system of claim 1 , wherein the waste chamber comprises an absorbent material that is configured to absorb waste liquids from the assay assembly.
9. A fluidic device comprising:
a sample collection unit configured to receive a sample of bodily fluid from a subject suspected to contain an influenza viral particle;
an assay assembly in fluidic communication with the sample collection unit, the assay assembly comprising a first reagent chamber, a second reagent chamber, a reaction site, and a fluidic channel that connects the first and second reagent chambers with the reaction site, wherein the first reagent chamber comprises a first immunoassay reagent and the second reagent chamber comprises a second immunoassay reagent; and
a waste chamber in fluidic communication with the assay assembly,
wherein the assay assembly is configured to:
receive the sample from the sample collection unit;
release the first and second immunoassay reagents from the first and second reagent chambers to the reaction site through the fluidic channel by one or more actuating elements;
allow the sample to react with the first and second immunoassay reagents at the reaction site, wherein the first immunoassay reagent binds to a hemagglutinin molecule to form a first immune complex on the influenza viral particle, and wherein the second immunoassay reagent binds to a neuraminidase molecule to form a second immune complex on the influenza viral particle;
yield one or more signals indicative of the simultaneous presence of hemagglutinin and neuraminidase on the influenza viral particle based on the first and second immune complexes; and
detect the influenza viral particle in the sample based on detection of the one or more signals indicative of the simultaneous presence of hemagglutinin and neuraminidase.
10. The fluidic device of claim 9 , wherein the one or more actuating elements comprise at least one pump and one valve to control and direct movement of fluids in the system.
11. The fluidic device of claim 9 , wherein detection of the one or more signals indicative of the simultaneous presence of hemagglutinin and neuraminidase is indicative of an influenza type A viral infection.
12. The fluidic device of claim 9 , wherein detection of the one or more signals indicative of the simultaneous presence of hemagglutinin and neuraminidase is indicative of an influenza type B viral infection.
13. The fluidic device of claim 9 , wherein the hemagglutinin is selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16, and the neuraminidase is selected from the group consisting of N1, N2, N3, N4, and N5.
14. The fluidic device of claim 9 , wherein the hemagglutinin is H5 and the neuraminidase is N1.